Results 151 to 160 of about 86,601 (293)

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma. [PDF]

Br J Haematol
Gordon MJ, Lakhotia R, Pittaluga S, Pack SD, Juanitez AM, Hamdy A, Johnson AJ, Frigault MM, Izumi R, Raffeld M, Roschewski M, Wilson WH, Melani C.   +12 more
europepmc   +1 more source

Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas [PDF]

, 2012
Zhaohui Wang, Lili Li, Xianwei Su, Zifen Gao, Gopesh Srivastava, Paul G. Murray, Richard F. Ambinder, Qian Tao   +7 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Global burden of non-Hodgkin lymphoma in the elderly: a population-based study using GBD 2021. [PDF]

Ann Hematol
Wang Y, Chen J, Guo J, Song Y, Zhu J, Ma J, Zhou M, Qi J, Liu W.   +8 more
europepmc   +1 more source

Five Cases of Non-Hodgkin B-Cell Lymphoma of the Ovary [PDF]

, 2014
Taylan Şenol, Emek Döğer, İlker Kahramanoğlu, Ayfer Gedük, Emre Köle, İzzet Yücesoy, Eray Çalışkan   +6 more
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Atypical presentation of high-grade non-Hodgkin lymphoma in a child: A diagnostic challenge. [PDF]

Radiol Case Rep
Elosiuba E, Elosiuba CH, Vella A, Yarfoh KB.   +3 more
europepmc   +1 more source

IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis [PDF]

, 2017
Elisa Ferretti, Emma Di Carlo, Emanuela Ognio, Giulio Fraternali Orcioni, Anna Corcione, Beatrice Belmonte, Jean Louis Ravetti, Claudio Tripodo, Doménico Ribatti, Vito Pistoia   +9 more
openalex   +1 more source

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT

, 2022
P. Borchmann, A. Lohneis, Philipp Gödel, Hyatt Balke‐Want, C Schmid, Francis Ayuk, Silke Holtkamp, L. Hanssens, Gregor Zadoyan, B. Friedrichs, Mario Assenmacher, Iris Bürger, Dina Schneider, Toon Overstijns, C. Scheid, Udo Holtick, Stefan Miltenyi, Michael Hallek   +17 more
openalex   +1 more source